Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils (TA1142)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2026
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Roflumilast for treating chronic obstructive pulmonary disease (TA461)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2017